News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Sequenom Inc. (SQNM) Laboratories Grants Nicox Exclusive Promotion And Marketing Rights For Its Retnagene™ AMD Test In North America


1/16/2014 9:10:45 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SOPHIA ANTIPOLIS, France and SAN DIEGO, Jan. 16, 2014 (GLOBE NEWSWIRE) -- Nicox S.A. (NYSE Euronext Paris: COX), and Sequenom, Inc. (NASDAQ:SQNM), today announced that their affiliate companies (Nicox Inc. and Sequenom Laboratories) have entered into an exclusive agreement in the age-related macular degeneration (AMD) field. As part of this agreement, Nicox has been granted the North American promotional rights to the Sequenom Laboratories RetnaGene(TM) AMD laboratory-developed test, for the evaluation of a patient's risk of AMD disease progression within 2, 5 and 10 years. The RetnaGene AMD test will be promoted by the same Nicox U.S. sales force which recently launched Sjö(TM), an advanced diagnostic panel for the early detection of Sjögren's Syndrome. Nicox expects to begin promoting the RetnaGene AMD test in the United States in the first half of 2014.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES